The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Open accessAbstract
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an essential negative regulator of T cell immune responses whose mechanism of action is the subject of debate. CTLA-4 shares two ligands (CD80 and CD86) with a stimulatory receptor, CD28. Here, we show that CTLA-4 can capture its ligands from opposing cells by a process of trans-endocytosis. After removal, these costimulatory ligands are degraded inside CTLA-4-expressing cells, resulting in impaired costimulation via CD28. Acquisition of CD86 from antigen-presenting cells is stimulated by T cell receptor engagement and observed in vitro and in vivo. These data reveal a mechanism of immune regulation in which CTLA-4 acts as an effector molecule to inhibit CD28 costimulation by the cell-extrinsic depletion of ligands, accounting for many of the known features of the CD28-CTLA-4 system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CTLA-4 may also remove CD80 and CD86 (including their cytoplasmic domains) from the cell surfaces of antigen-presenting cells via trans-endocytosis (24), therefore reducing the availability of these stimulatory receptors to other CD28-expressing T cells.”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [24]
In the citing paper
“It is thought that the blockade of CTLA-4 most likely impacts the stage of T cell activation in the draining lymph nodes when CTLA-4 expressing Tregs remove CD80/CD86 from the surface of antigen-presenting cells, thereby reducing their ability to effectively stimulate tumor-specific T cells (24).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [24]
In the citing paper
“Additionally, CTLA-4 could capture, remove, and degrade its ligands CD80/CD86 from nearby APCs by trans-endocytosis, further hampering the co-stimulatory signal [125].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [125]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
Plat-E: an efficient and stable system for transient packaging of retroviruses
MORITA, S., Kojima, T., & Kitamura, T. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301206 · Cited by 1,660
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967
CD28 and CTLA-4 coreceptor expression and signal transduction
Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898
Onishi, Y., Fehervari, Z. T., Yamaguchi, T., & Sakaguchi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711106105 · Cited by 754
B cells acquire antigen from target cells after synapse formation
Batista, F. D., Iber, D., & Neuberger, M. S. (2001) · Nature · doi:10.1038/35078099 · Cited by 629
A MOLECULAR PERSPECTIVE OF CTLA-4 FUNCTION
Teft, W. A., Kirchhof, M. G., & Madrenas, J. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090535 · Cited by 526
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,001
CAR ‐T cell therapy in melanoma: A future success story?
Simon, B., & Uslu, U. (2018) · Experimental Dermatology · doi:10.1111/exd.13792 · Cited by 69
Eso, Y., & Seno, H. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820948773 · Cited by 67
Therapeutic potential of interleukin-2 in autoimmune diseases
Yuan, Y., Kolios, A. G. A., Liu, Y., Zhang, B., Li, H., Tsokos, G. C., & Zhang, X. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.04.010 · Cited by 68
Belatacept: from rational design to clinical application
Wekerle, T., & Grinyo, J. M. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01386.x · Cited by 70
Johnson, M. (2012) · Materials and Methods · doi:10.13070/mm.en.2.113 · Cited by 75
Wang, S., Li, H., Li, B., Xie, T., Zhu, T., Sun, L., Ren, H., & Ye, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.016 · Cited by 67
Safinia, N., Grageda, N., Scottà, C., Thirkell, S., Fry, L., Vaikunthanathan, T., Lechler, R. I., & Lombardi, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00354 · Cited by 68
Céspedes, P. F., Jainarayanan, A., Fernández‐Messina, L., Valvo, S., Saliba, D. G., Kurz, E., Kvalvaag, A. S., Chen, L., Ganskow, C. S. G., Colin‐York, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31160-3 · Cited by 66
Cancer stem cells, lymphangiogenesis, and lymphatic metastasis
Li, S., & Li, Q. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.013 · Cited by 67
New Therapies in Head and Neck Cancer
Santuray, R. T., Johnson, D. E., & Grandis, J. R. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.03.006 · Cited by 67
Vieyra-Lobato, M. R., Vela‐Ojeda, J., Montiel‐Cervantes, L. A., López‐Santiago, R., & Moreno-Lafont, M. C. (2018) · Journal of Immunology Research · doi:10.1155/2018/3758713 · Cited by 67
Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells
Kumar, P., Saini, S., Khan, S. M., Lele, S. S., & Prabhakar, B. S. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.09.008 · Cited by 70
Condomines, M., Arnason, J. E., Benjamin, R., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130518 · Cited by 68
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66
The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era
Spyrou, N., Vallianou, N. G., Kadillari, J., & Dalamaga, Μ. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.008 · Cited by 66
DCision-making in tumors governs T cell anti-tumor immunity
Alfei, F., Ho, P., & Lo, W. (2021) · Oncogene · doi:10.1038/s41388-021-01946-8 · Cited by 68
Bornyl acetate: A promising agent in phytomedicine for inflammation and immune modulation
Zhao, Z., Sun, Y., & Ruan, X. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154781 · Cited by 70
The immunopathogenesis of sarcoidosis
Miedema, J., Cinetto, F., Smed‐Sörensen, A., & Spagnolo, P. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103247 · Cited by 76
Jeffery, H. C., Jeffery, L. E., Lutz, P. L., Corrigan, M., Webb, G. J., Hirschfield, G. M., Adams, D., & Oo, Y. H. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.12940 · Cited by 66
Self-citationWang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Foxp3+ Regulatory T Cells in Bone and Hematopoietic Homeostasis
Fischer, L., Herkner, C., Kitte, R., Dohnke, S., Riewaldt, J., Kretschmer, K., & Garbe, A. I. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00578 · Cited by 64
Rudqvist, N.-P., Charpentier, M., Lhuillier, C., Wennerberg, E., Spada, S., Sheridan, C. K., Zhou, X. K., Zhang, T., Formenti, S. C., Sims, J. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40844-3 · Cited by 68
IL-23 stabilizes an effector Treg cell program in the tumor microenvironment
Wertheimer, T., Zwicky, P., Rindlisbacher, L., Sparano, C., Vermeer, M., de Melo, B. M. S., Haftmann, C., Rückert, T., Sethi, A., Schärli, S., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01755-7 · Cited by 70
The confluence of radiotherapy and immunotherapy
Burnette, B., Fu, Y., & Weichselbaum, R. R. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00143 · Cited by 65
T Cell Cosignaling Molecules in Transplantation
Ford, M. L. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.012 · Cited by 67
Differential roles of regulatory T cells in acute respiratory infections
Jovisic, M., Mambetsariev, N., Singer, B. D., & Morales‐Nebreda, L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170505 · Cited by 68
H-Ras transfers from B to T cells via tunneling nanotubes
Rainy, N., Chetrit, D., Rouger, V., Vernitsky, H., Rechavi, O., Marguet, D., Goldstein, I., Ehrlich, M., & Kloog, Y. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.245 · Cited by 67
Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
Schneider, H., & Rudd, C. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00619 · Cited by 65
The Role of Coinhibitory Signaling Pathways in Transplantation and Tolerance
McGrath, M. M., & Najafian, N. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00047 · Cited by 63
Olesch, C., Sha, W., Angioni, C., Sha, L. K., Açaf, E., Patrignani, P., Jakobsson, P., Radeke, H. H., Grösch, S., Geißlinger, G., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3581 · Cited by 64
Roth, G. S., & Decaens, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.010 · Cited by 66
Uhlig, H. H., & Schwerd, T. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000614 · Cited by 63
Taghizade, N., Babayeva, R., Kara, A., Karakuş, İ. S., Çatak, M. C., Bulutoğlu, A., Haskoloğlu, Z. Ş., Hacı, İ. A., Dalgıç, C. T., Karabıber, E., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.08.004 · Cited by 63
Worboys, J. D., Vowell, K. N., Hare, R. K., Ambrose, A. R., Bertuzzi, M., Conner, M. A., Patel, F., Zammit, W. H., Moya, J. G., Hazime, K. S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40755-3 · Cited by 59
Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity
Kennedy, P. T., Saulters, E. L., Duckworth, A. D., Lim, Y. J., Woolley, J. F., Slupsky, J. R., Cragg, M. S., Ward, F. J., & Dahal, L. N. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.028 · Cited by 63
Promoting transplantation tolerance; adoptive regulatory T cell therapy
Safinia, N., Leech, J. M., Hernández-Fuentes, M. P., Lechler, R. I., & Lombardi, G. (2012) · Clinical & Experimental Immunology · doi:10.1111/cei.12052 · Cited by 64
EFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasis
Walker, L. S. K. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.02.007 · Cited by 63
Self-citationNox2 in regulatory T cells promotes angiotensin II–induced cardiovascular remodeling
Emmerson, A. C., Trevelin, S. C., Mongue‐Din, H., Becker, P. D., Ortiz, C., Smyth, L. A., Peng, Q., Elgueta, R., Sawyer, G. J., Ívetic, A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97490 · Cited by 63
Regulatory T Cells: From Discovery to AutoimmunityPreprint
Kitz, A., Singer, E. R., & Hafler, D. A. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029041 · Cited by 71
Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia
Sarkar, D., Biswas, M., Liao, G., Seay, H. R., Perrin, G. Q., Markusic, D. M., Hoffman, B. E., Brusko, T. M., Terhorst, C., & Herzog, R. W. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.30 · Cited by 62
Mirzaei, H. R., Pourghadamyari, H., Rahmati, M., Mohammadi, A., Nahand, J. S., Rezaei, A., Mirzaei, H., & Hadjati, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.03.010 · Cited by 62
Magee, C. N., Boenisch, O., & Najafian, N. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04180.x · Cited by 72
Disrupted regulatory T cell homeostasis in inflammatory bowel diseases
Pedros, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.974 · Cited by 63
Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
Targeting tumor-infiltrating tregs for improved antitumor responses
Qin, D., Zhang, Y., Shu, P., Lei, Y., Li, X., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1325946 · Cited by 63
Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies?
Taghizadeh-Anvar, M., Rashidan, K., Arsam, N., Rasouli‐Saravani, A., Yadegari, H., Ahmadi, A., Asgari, Z., Vanan, A. G., Ghorbaninezhad, F., & Tahmasebi, S. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03525-9 · Cited by 67
Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition
Brzostek, J., Gascoigne, N. R. J., & Rybakin, V. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00024 · Cited by 65
Immune checkpoint inhibitors for cancer treatment
Park, J., Kwon, M., & Shin, E. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0850-5 · Cited by 61
Compagno, D., Tiraboschi, C., Garcia, J. D. G., Rondón, Y., Corapi, E., Velazquez, C., & Laderach, D. J. (2020) · Biomolecules · doi:10.3390/biom10050750 · Cited by 61
Schlöder, J., Shahneh, F. Z., Schneider, F.-J., & Wieschendorf, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.973813 · Cited by 63
Du, G., Dou, C., Sun, P., Wang, S., Liu, J., & Ma, L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1431211 · Cited by 65
Ville, S., Poirier, N., Blancho, G., & Vanhove, B. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00411 · Cited by 65
Jeffery, H. C., Braitch, M. K., Brown, S., & Oo, Y. H. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00334 · Cited by 60
Regulatory T cell therapy: Current and future design perspectives
Rana, J., & Biswas, M. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104193 · Cited by 58
T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity
Canel, M., Taggart, D., Sims, A. H., Lonergan, D. W., Waizenegger, I. C., & Serrels, A. (2020) · eLife · doi:10.7554/elife.48092 · Cited by 62
Biomimetic immunomodulation by crosstalk with nanoparticulate regulatory T cells
Li, S., Wang, L., Gu, Y., Lin, L., Zhang, M., Jin, M., Mao, C., Zhou, J. M., Zhang, W., Huang, X., et al. (2021) · Matter · doi:10.1016/j.matt.2021.08.015 · Cited by 58
Gnawing Between Cells and Cells in the Immune System: Friend or Foe? A Review of Trogocytosis
Zhao, S., Zhang, L., Xiang, S., Hu, Y., Wu, Z., & Shen, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.791006 · Cited by 62
van Pul, K. M., Notohardjo, J. C. L., Fransen, M. F., Koster, B. D., Stam, A. G. M., Chondronasiou, D., Lougheed, S. M., Bakker, J., Kandiah, V., van den Tol, M. P., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8097 · Cited by 58
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Regulatory T Cells Require TCR Signaling for Their Suppressive Function
Schmidt, A. M., Lu, W., Sindhava, V. J., Huang, Y., Burkhardt, J. K., Yang, E., Riese, M. J., Maltzman, J. S., Jordan, M. S., & Kambayashi, T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402384 · Cited by 63
CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis
Safari, F., Farajnia, S., Aria, M., Zarredar, H., & Nasrolahi, A. (2018) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2018.1437625 · Cited by 58
Zhou, S., Khanal, S., & Zhang, H. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s193338 · Cited by 58
Control of foreign Ag‐specific Ab responses by Treg and Tfr
Wing, J. B., Lim, E. L., & Sakaguchi, S. (2020) · Immunological Reviews · doi:10.1111/imr.12888 · Cited by 58
Othy, S., Jairaman, A., Dynes, J. L., Dong, H., Tune, C., Yeromin, A. V., Zavala, A., Akunwafo, C., Chen, F., Parker, I., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006895117 · Cited by 57
Gogishvili, T., Lühder, F., Goebbels, S., Beer‐Hammer, S., Pfeffer, K., & Hünig, T. (2012) · European Journal of Immunology · doi:10.1002/eji.201242824 · Cited by 57
Induction of transplantation tolerance through regulatory cells: from mice to men
Ferrer, I. R., Hester, J., Bushell, A., & Wood, K. J. (2014) · Immunological Reviews · doi:10.1111/imr.12158 · Cited by 58
Requirement of full TCR repertoire for regulatory T cells to maintain intestinal homeostasis
Nishio, J., Baba, M., Atarashi, K., Tanoue, T., Negishi, H., Yanai, H., Habu, S., Hori, S., Honda, K., & Taniguchi, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516617112 · Cited by 62
Jeffery, L. E., Qureshi, O. S., Gardner, D. H., Hou, T. Z., Briggs, Z., Soskic, B., Baker, J., Raza, K., & Sansom, D. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131539 · Cited by 57
Self-citationLuo, T., Ji, W., Yuan, F., Guo, Z.-Z., Li, Y.-X., Dong, Y., Ma, Y., Zhou, X., & Li, Y. (2016) · Scientific Reports · doi:10.1038/srep26767 · Cited by 58
Salama, A. K. S., & Moschos, S. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw534 · Cited by 56
The Impact of Dietary Components on Regulatory T Cells and Disease
Hornero, R. A., Hamad, I., Côrte‐Real, B. F., & Kleinewietfeld, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00253 · Cited by 61
Berezhnoy, A., Sumrow, B. J., Stahl, K., Shah, K., Liu, D., Li, J., Hao, S.-S., De Costa, A., Kaul, S., Bendell, J., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100163 · Cited by 56
Turning the Tide Against Regulatory T Cells
Han, S., Toker, A., Liu, Z. Q., & Ohashi, P. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00279 · Cited by 58
Lui, P. P., Cho, I., & Ali, N. (2020) · Immunology · doi:10.1111/imm.13208 · Cited by 61
Richardson, N., Wootton, G. E., Bozward, A. G., & Oo, Y. H. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00940-w · Cited by 58
Regulatory T Cell Induction, Migration, and Function in Transplantation
Burrell, B. E., Nakayama, Y., Xu, J., Brinkman, C. C., & Bromberg, J. S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202027 · Cited by 57
Basso, D., Fogar, P., Falconi, M., Fadi, E., Sperti, C., Frasson, C., Greco, E., Tamburrino, D., Teolato, S., Moz, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054824 · Cited by 56
Pen, J. J., Keersmaecker, B. D., Maenhout, S. K., Nuffel, A. M. T. V., Heirman, C., Corthals, J., Escors, D., Bonehill, A., Thielemans, K., Breckpot, K., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201008 · Cited by 54
Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment
Zhao, Z., Xiao, X., Saw, P. E., Wu, W., Huang, H., Chen, J., & Nie, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9665-8 · Cited by 56
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Tung, S. L., Fanelli, G., Matthews, R. I., Bazoer, J., Letizia, M., Vizcay‐Barrena, G., Faruqu, F. N., Philippeos, C., Hannen, R. F., Al‐Jamal, K. T., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00317 · Cited by 55
Bolivar-Wagers, S., Larson, J. H., Jin, S., & Blazar, B. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864748 · Cited by 59
FOXP3+ regulatory T cells and the immune escape in solid tumours
Qiu, Y., Ke, S., Chen, J., Qin, Z., Zhang, W., Yuan, Y., Meng, D., Zhao, G., Wu, K., Li, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982986 · Cited by 63
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 61
Gannavaram, S., Bhattacharya, P., Ismail, N., Kaul, A., Singh, R. K., & Nakhasi, H. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00187 · Cited by 55
Patsoukis, N., Weaver, J. D., Strauss, L., Herbel, C., Seth, P., & Boussiotis, V. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00330 · Cited by 57
Matoba, T., Imai, M., Ohkura, N., Kawakita, D., Ijichi, K., Toyama, T., Morita, A., Murakami, S., Sakaguchi, S., & Yamazaki, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.32024 · Cited by 54
Lax, B. M., Palmeri, J. R., Lutz, E. A., Sheen, A. M., Stinson, J. A., Duhamel, L., Santollani, L., Kennedy, A., Rothschilds, A. M., Spranger, S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300895120 · Cited by 54
Self-citationCTLA-4 tail fusion enhances CAR-T antitumor immunity
Zhou, X., Cao, H., Fang, S., Chow, R. D.-W., Tang, K., Majety, M., Bai, M., Dong, M. B., Renauer, P. A., Shang, X., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01571-5 · Cited by 57
Emerging Co-signaling Networks in T Cell Immune Regulation
Jung, K., & Choi, I. (2013) · Immune Network · doi:10.4110/in.2013.13.5.184 · Cited by 54
Hu, P., Liu, Q., Deng, G., Zhang, J., Liang, N., Xie, J., & Zhang, J. (2017) · Scientific Reports · doi:10.1038/srep42913 · Cited by 54
Signals that drive T follicular helper cell formation
Webb, L. M. C., & Linterman, M. A. (2017) · Immunology · doi:10.1111/imm.12778 · Cited by 55
Surface Oncology, 5. H. S., Rausch, M. P., & Hastings, K. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch9 · Cited by 56
New advances in immunotherapy for non-small cell lung cancer.
Qin, H., Wang, F., Liu, H., Zeng, Z., Wang, S., Pan, X. H., & Gao, H. (2018) · Europe PMC (PubMed Central) · Cited by 52
Wang, Z., Guo, X., Gao, L., Deng, K., Lian, W., Bao, X., Feng, M., Duan, L., Zhu, H., & Xing, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa449 · Cited by 54
Gavali, S., Liu, J., Li, X., & Paolino, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910800 · Cited by 53
Immune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 54
The Genetic Basis of Graves Disease
Płoski, R., Szymanski, K., & Bednarczuk, T. (2011) · Current Genomics · doi:10.2174/138920211798120772 · Cited by 55
Qualai, J., Li, L., Cantero-Pérez, J., Tarrats, A., Fernández, M. A., Sumoy, L., Rodolosse, A., McSorley, S. J., & Genescà, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154253 · Cited by 53
Metadata
- Authors
- Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., Hou, T. Z., Futter, C. E., Anderson, G., Walker, L. S. K., & Sansom, D. M.
- Affiliations
- University of Birmingham (GB)
- University College London (GB)
- Corresponding author
- Sansom, David M.
- ORCID
- Venue
- Science
- Published
- 2011-04-29
- Volume
- 332
- Issue
- 6029
- Pages
- 600-603
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3198051
- OpenAlex
- W2087482409
- Cited by
- 1,860
- References
- 33
- Citations by year
- 2026: 128 · 2025: 140 · 2024: 153 · 2023: 155 · 2022: 160 · 2021: 151 · 2020: 149 · 2019: 119 · 2018: 126 · 2017: 103 · 2016: 105 · 2015: 100 · 2014: 84 · 2013: 82 · 2012: 68
- FWCI
- 38.16
- Type
- journal article
- Language
- en
- Open access
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Aston Publications Explorer (Aston University) (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Wellcome Trust
- Versus Arthritis (17851)
- Biotechnology and Biological Sciences Research Council (BB/H013598/1, BB/D011000/1)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, CD80, CD86, CD28, trans-endocytosis, costimulation, T cell regulation, T cell receptor engagement, antigen-presenting cells, ligand degradation
- MeSH terms
- Animals, Cricetulus, Dendritic Cells, Endocytosis, Cricetinae, Humans, Ligands, Lymphocyte Activation, Mice, Transgenic, Models, Biological, Ovalbumin, Receptors, Antigen, T-Cell, Recombinant Fusion Proteins, Antigens, CD, T-Lymphocyte Subsets, CHO Cells, CD28 Antigens, B7-1 Antigen, Jurkat Cells, T-Lymphocytes, Regulatory, Mice, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
